Cogent Biosciences
COGT
36 hedge funds and large institutions have $17.8M invested in Cogent Biosciences in 2019 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 12 reducing their positions, and 9 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
24% more capital inflows, than outflows
Capital inflows: $2.5M | Capital outflows: $2.02M
2.36% less ownership
Funds ownership: 42.7% → 40.34% (-2.4%)
8% less funds holding
Funds holding: 39 → 36 (-3)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
42% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$240K |
| 2 |
Morgan Stanley
New York
|
+$150K |
| 3 |
Oxford Asset Management
Oxford,
United Kingdom
|
+$141K |
| 4 |
Bridgeway Capital Management
Houston,
Texas
|
+$91.5K |
| 5 |
Goldman Sachs
New York
|
+$91.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$447K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$332K |
| 3 |
Millennium Management
New York
|
-$248K |
| 4 |
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$139K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$133K |
COGT Hedge Fund Activity: Q3 2019 in Review
36 of the 4,576 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q3 2019, worth a combined $17.8M — down 47% from $33.7M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of COGT and 7 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 7 added.
The largest buyer was Vanguard Group, adding an estimated $240K. The largest seller was Platinum Investment Management, exiting entirely with an estimated $447K sold.
- 36 institutional investors held Cogent Biosciences (COGT) as of Q3 2019, down from 39 in Q2 2019.
- Funds reported $17.8M of Cogent Biosciences stock for Q3 2019, down 47% quarter-over-quarter.
- 7 funds opened new Cogent Biosciences positions in Q3 2019 and 9 closed out, a net change of -2 holders.
- The largest Cogent Biosciences buyer in Q3 2019 was Vanguard Group, an estimated $240K added.
- The largest Cogent Biosciences seller in Q3 2019 was Platinum Investment Management, an estimated $447K sold.
Based on aggregated 13F filings for Q3 2019.